| [ Summary ] |
The positive ratio of hepatitis C virus (HCV) is high in dialysis and kidney transplant patients. Long-term HCV infection is considered an important factor for graft and patient survival because of the complications caused by chronic hepatitis C (CHC), liver cirrhosis, and cancer. Long-term interferon or peginterferon treatment is used in patients with CHC. However, treatment was limited due to low HCV exclusion rate and complications. Recently, direct-acting antivirals (DAA) have been developed. Results have significantly improved but, in dialysis and kidney transplant patients, renal function and drug interaction must be considered when selecting DAA. Positive DAA treatment of CHC in dialysis and kidney transplant patients with HCV should improve prognosis. For HCV-positive dialysis patients who want to undergo kidney transplantation, aggressive DAA treatment can improve patient survival. |